Vinorelbine - A clinical review

British Journal of Cancer

Volumn 82, Issue 12, 2000, Pages 1907-1913

  Gregory, R K ^a   Smith, I E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; NAVELBINE; PLANT EXTRACT; TUBULIN; VINCRISTINE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; CELL DIVISION; CHEMICAL STRUCTURE; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; VINBLASTINE;

EID: 0034074996     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Adenis A, Vanlemmmens L, Fournier C, Hecquet B and Bonneteere J (1996) Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable loco-regional breast cancer. Breast Cancer Res and Treat 40: 161-169
2. Arca R, Fernadez E and Ivulich C (1998) Navelbine (N) and Doxorubicin (A) as first line chemotherapy in metastatic breast cancer. Proc 8th Internat Congress on anti-cancer chemotherapy: Abstract P116
3. Ashizawa T, Miyoshi K, Asada M, Kobayashi E, Okabe M, Morimoto M, Gomi K and Hirata T (1993) Anti-tumour activity of navelbine, a new vinca-alkaloid analog. Gan To Kagaku Ryoho 20: 59-66
4. Baldini E, Tibaldi C, Ardizzoni A, Salvati F, Antilli A, Portalone L, Barbera S, Romano F, De Marinis F, Miglioino MR,Noseda MA, Borghini U, Crippa M, Ferrara G, Raimondi M, Fioretti M, Bandera M, Pennucci MC, Galeasso G, Cacciani GC, Lepidini G, Sunseri G, Lanfranco C, Rinaldi M and Rosso R (1998) Cisplatin-vindesine-mitomycin (MVP) vs Cisplatin-vinorelbine-ifosfamide (PIN) versus carboplatin-vinorelbine (CaN): a FONICAP phase II study. Br J Cancer 77: 2367-70
5. Besenval M, Delgado M, Demarez JP and Krikorian A (1989) Safety and tolerance of Navelbine in phase I-II clinical trials. Semin-Oncol 16 (2 suppl 4): 37-40
6. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP and Meniniger V (1989) In situ analysis of the action of Navelbine on microtubules using immunofluoresence. Semin Oncol 16 (suppl 4): 5-8
7. Binet S, Chaineau E, Fellous A, Lataste H, Krikorian A, Couzinier JP and Meninger V (1990) Immunofluoresence study of the action of Navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer 46: 262-266
8. Blajman C, Balbiani L, Block J, Bianchi R, Temperly G, Chacon R. Capa A, Coppola F, Bader M and Giachella O (1996) Phase III study: Navelbine plus adriamycin versus flurouracil plus adriamycin plus cyclophosphamide in advanced breast cancer. Ann Oncol 76 (7 suppl 5): Abstract PH2
9. Bore P, Rahmani R, Van Cantfort J, Focan C and Cano JP (1989) Pharmacokinetics of a new anticancer drug, navelbine in patients. Cancer chemother pharmacol 23: 247-251
10. Bruno S, Puerto VL, Mickiewicz E, Hegg R, Texeira LC, Gaitan L, Martinez L, Fernadez O, Otero J and Kesselring J (1995) Phase II trial of weekly IV vinorelbine as a single agent in first-line advanced breast cancer chemotherapy: The Latin-American experience. Am J Clin Oncol 18: 392-396
11. Canobbio L, Boccardo F, Pastorini G, Brenna F, Martini C, Resasco M and Santi L (1989) Phase II study of Navelbine in advanced breast cancer. Semin Oncol 16: 33-36
12. Carmicheal J, Hegg R, Firat D, Pawlicki M, Le bras F, Delgado FM, Danel P and Johnson SAN (1997) Navelbine and fractionated dose doxonibicin improves first line advanced breast cancer. Br J Cancer 75 (suppl 1): Abstract P85
13. Chadjaa M, Izzo J and May-Levin F (1993) Preliminary data on 4'epiadriamycin (EPI)-vinorelbine (VNB): a new active combination in advanced breast cancer. Proc Annu Meet Am Soc Clin Oncol 12: Abstract 152
14. Chang AY, Boros L, Garrow GC, Asbury RF and Hui L (1996) Ifosfamide, carboplatin, etoposide and paclitaxel chemotherpay: a dose escalation study Semin Oncol 23 (3 suppl 6): 74-7
15. Colucci G, Gebbia V, Galetta D, Riccardi F, Cariello S and Gebbia N (1997) Cisplatin and Navelbine followed by Ifosfamide and Epirubicin versus the opposite sequence in advanced unresectable stage III and IV NSCLC. Br J Cancer 76: 1509-1517
16. Cros S, Wright M, Morimoto M, Lataste JP and Krikorian A (1989) Experimental anti-tumour activity of Navelbine. Semin Oncol 16: 15-20
17. Cvittovic E and Izzo J (1992) The current and future place of Vinorelbine in cancer therapy. Drugs 44 (suppl 4): 36-45
18. Depierre A, Lemarie E and Dabouis G (1991) A phase II study of Navelbine (vinorelbine) in the treatment of non small cell lung cancer. Am J Clin Oncol 14:115-119
19. Debal V, Morjani H, Millot JM, Angiboust JF, Gourdier B and Manfait M (1992) Determination of vinorelbine (Navelbine) in tumour cells by high performance liquid chromatography. J Chromatogr Biomed Appl 581: 93-9
20. Devizzi L, Santoro LA, Bonfante LV, Viviani S, Balzarini, Valagussa P and Bunadonna G (1994) Vinorelbine: An active drug for the management of patients with heavily pre-treated Hodgkin's disease. Ann Oncol 5: 817-820
21. Dieras V, Extra JM, Bellisant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P and Marty M (1996) Efficacy and tolerance of vinorelbine and flurouracil combination as first line chemotherapy of advanced breast cancer. JCO 14: 3097-3104
22. Dubos C, Prevost JN, Brun J and Rousselot P (1991) Infarctus myocardique et vinorelbine. Rev Mal Resp 8: 299-300
23. Felip E, Del Campo JM, Bodi R, Vera R, Casado S and Rubio D (1997) Cisplatin and navelbine followed by radiotherapy in the treatment of stage III and IV NSCLC patients. Am J Clin Oncol 20: 404-406
24. Frasci G, Panza N, Comella P, Nicolella GP, Natale M, Pacilio C, Gravina A, Caputi V, Botti G and Comella G (1997) Cisplatin, Gemeitabine and Navelbine in locally advanced or metastatic NSCLC - phase II study. Ann Oncol 8: 1045-1048
25. Fumoleau P, Delgado FM, Delozier T, Monnier A, Delgado G, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MJ, Chollet P, Lecourt L and Montcuquet P (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. JCO 11: 1245-52
26. Furuse K, Kubota K and Kawahara M (1994) A phase II study of Vinorelbine, a new derivative of vinca alkaolid, for previously untreated advanced non small cell lung cancer. Lung Cancer 11: 385-391
27. Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Olivra C, de Pablo JL, Gorostiago J, Giron GC and Cervantes A (1994) Phase II trial of weekly IV vinorelbine in first line advanced breast cancer chemotherapy. Annal Oncol 5: 854-857
28. Gebbia V, Caruso M, Valenza R, Testa A, Cannata G, Verderame F, Cipolla C, Curto G, Oliveri D, Chiarenza M, Latteri MA, Di Gesu G and Gebbia N (1994) Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung cancer. Anticancer Research 14: 1247-1250
29. Gershenson DM, Burke DW, Morris M, Bast RC, Guaspari A, Hohneker J and Wharton JT (1998) A phase I study of a daily ×3 schedule of intravenous vinorelbine for refractory epithelial ovarian carcinoma. Gvnecol-Oncol 70: 404-9
30. Gil Deza E, Balbiani L, Coppola F, Blajman C, Block JF, Giachella O, Chacon R, Capo A, Zori-Comba-A, Fein L, Polera L, Matwiejuk M, Jaremtchuk A, Muro H, Reale M, Bass C, Chiesa G, Van-Koten M and Schmilovich A (1996) Phase III study of Navelbine (NVB) vs NVB plus cisplatin in non small cell lung cancer (NSCLC) Stage IIIb or IV. Proc-Annu-Meet-AM-Soc-Clin-Oncol 15: A1193
31. Gridelli C, Perrone F, Ianniello GP, Brancaccio L, Iaffaioli RV, Curcio C, D'Aprile M, Cioffi R, Cigolari S, Rossi A, Palazzolo G, Veltri E, Pergola M, De-Placido S, Gallo C, Monfardini S and Bianco AR (1998) Carboplatin plu vinorelbine, a new well tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. JCO 16: 1414-9
32. Gridelli C, Perrone F, Gallo C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo F, D'Aprile M, Rossi A, Migliorino R, Bartoluscei R, Bianco AR, Pergola M and Monfardini S (1997) Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer, a two-stage phase II study. Eur J Cancer 33: 392-397
33. Haldar S, Jena N and Croce CM (1995) Inactivation of Bcl2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507
34. Harousseau JL, Maloisel F, Sotto JJ, Facon TH, Child T, Kelsey SM, Johnson S, Descheemaker B and Moore L (1997) Vinorelbine in patients with recurrent multiple myelomas: a phase II study. Annu Meet Am Soc Clin Oncol 16: Abstract 37
35. Hochster H (1994) A multicenter Phase II study of navelbine (NVB) and doxorubicin (DOX) as first line chemotherapy of metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 13: Abstract 203
36. Jehl F, Quoix E, Leveque D, Pauli G, Breillout F, Krikorian A and Monteil H (1991) Pharmacokinetics and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 47: 2073-6
37. Jehl F, Debs J and Herline C (1990) Determination of Navelbine and desacetylnavelbine in biological fluids by high performance liquid chromatography. J Chromatogr 525: 225-33
38. Johnson IS, Wright HF, Svoboda GH and Vlantis J (1960) Antitumour principles derived from vinea rosea Linn: I. Vinca leucoblastine and leurosine. Cancer Res 20: 1016-1022
39. Khayat D, Covelli A, Variol P, Benhamouda A, Jacques C and Bugat R (1995) Phase I and pharmacologic study of intravenous (IV) vinorelbine in patients with solid tumours. Proc Annu Meet Am Soc Clin Oncol 14: Abstract 1518
40. Kobayashi S, Sakai T, Dalrymple PD, Wood SG and Chasseaud LF (1993) Disposition of the the novel anti-cancer agent vinorelbine ditartrate following Intravenous administration on mice, rats and dogs. Arzneimittrl-Forschung 43: 1367-77
41. Kusunoki Y, Furuse K, Yamori S, Negros S, Katagami N, Takada K, Kinuwaki E and Niitani H (1995) Randomised phase II study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated non small cell lung cancer Final results. Proc Annu Meet Am Soc Clin Oncol 14: A1071 1995
42. Le Chevalier T, Brisgand D, Doulliard J-Y, Pujal , Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigarola S, Gottifred M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P and Tursz T (1994) Randomised study of vinorelbine and cisplatin versus vendesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European Multi-centre trial including 621 patients. JCO 12: 360-367
43. Leveque D, Jehl F, Quoix E and Breillout F (1992) Clinical pharmacokinetics of vinorelbine alone and when combined with cisplatin. J Clin Pharmacol 32: 1096-98
44. Leveque D, Quoix E, Dumont P, Massard G, Hentz JG, Charloux A and Jehl F (1993) Pulmonary distribution of vinorelbine in patients with non small cell lung cancer. Cancer Chemother Pharmacol 33: 176-178
45. Lucas S, Donehower R, Rowinsky E, Wargin W, Hohneker J, Hseih A and Donehower R (1992) Weekly Navelbine liquid filled soft gelatin capsules at full therapeutic doses in patients with solid tumours. Ann Oncol 3 (suppl 1): 125
46. Malzyner A, Bruno S, Piris N, Agnelli A, Gampel O, Fraga J, Le Pape I, Martinez A, Delgado FM and Delgado GL (1991) Randomised phase II study of Navelbine (NVB) vs NVB + CDDP (NP) in patients with inoperable non small cell lung cancer. Eur J Cancer 27 (suppl 2): Abstract S1048
47. Mathe G and Reizenstein P (1985) Phase I pharmacological study of a new vincaalkaloid - Navelbine. Cancer Lett 27: 285-293
48. Mattioli R, Imperatori L and Casadei V (1997) The impact of vinorelbine in elderly (aged >70 years) with NSCLC: a preliminary report. Eur J Cancer 33: Abstract 1086
49. Marquet P, Lachetre G, Debord J, Eichler B, Bonnaud F and Nicot G (1992) Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42: 545-547
50. Masters GA, Hoffman PL, Drinkard LC, Samuels BL, Golomb HM and Vokes EE (1998) A review of Ifosfamide and Vinorelbine in advanced NSCLC. Semin Oncol 25 (1 suppl 2): 8-14
51. Meninger V, Binet S and Fellous A (1989) etude en immunofluorescence de l'action de la Navelbine sur differents types de microtubules. Bull Cancer 76: Abstract
52. Morris M, Brader KR, Levenback C, Burke TW, Atkinson EN, Scott WR and Gershenson DM (1998) Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. JCO 16:1094-8
53. Mouridsen HT (1992) Systemic therapy of advanced breast cancer. Drugs 44 (suppl 4): 17-28
54. Namer P, Soler-Michel P and Mefti F (1997) Is the combination of FAC/FEC always the best regimen in advanced breast cancer? Utility of mitoxantrone and navelbine as an alternative in some situations. Results of a phase III randomised trial. Breast Cancer Res Treat 46: Abstract 406
55. Nistico G, Garufi C, Pace R, Galla DPG, Barni S, Frontini L and Terzoli E (1997) Weekly epirubicin and vinorelbine plus GCSF in metastatic breast cancer: high activity with 75% survival rate at 2 years. Proc Am Soc Clin Oncol 16: Abstract 647
56. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using up-dated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909
57. Paintrand MR and Pignot I (1983) Navelbine: an ultrastructural study of its effects. J Electron Microsc 32: 115-124
58. Pierre Fabre Medicament (1993) Internal report. PFM259 P.36 (2)
59. Rahmani R, Bruno R, Iliadis A, Favre R, Just S, Barbet J and Cano JP (1984) Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5′noranhydrovincristine (Navelbine). Cancer Res 44: 5609-5613
60. Rinaldi M, Della Giulia M, Venturo I, Del Medico P, Serrone L, Capomolla and Lopez M (1994) Vinorelbine as single agent in advanced non small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol 13: Abstract 1212
61. Rittenberg CN, Gralla RJ and Rehmeyer TA (1995) Assessing and managing venous irritation associated with vinorelbine tartrate. Oncol Nurs Forum 22: 707-710
62. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R,Civas MA, Machiavelli M, Lacava JA, Langhi M and Romero-Acuna L (1994) Vinorelbine as first line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12: 336-341
63. Romero Acuna R, Langhi M, Perez J, Leone B, Machiavelli M, Lacava, Vallejo C, Romero A, Cuevas M, Ortiz E, Grasso S, Amato S, Salvadori M, Rodriguez R, Barbieri M and Romera-Acuna J (1998) Vinorelbine and Paclitaxel as first-line chemotherapy in metastatic breasy cancer: final results. Proc Annu Meet Am Soc Clin Oncol 17: abstract 658
64. Santamaggio C, Tulli E, Rinaldini M, Algeri R, Righi R, Pepi F, Ghezzi P, Andrei A and Bellaza A (1996) Carboplatin and Navelbine in the treatment of advanced NSCLC: a multi-centre phase II study. Am J Clin Oncol 21: 67-71
65. Smith TJ, Hillner BF, Neighbors DM, McSorley PA and Le Chevalier T (1995) Economic evaluation of a randomised clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. JCO 132: 2166-2173
66. Spicer D, McCaskill-Stevens W, Oken M, Abrams J, Hines J, Cooper B, Craig J, Bertsch L and Hoeneker J (1994) Oral Navelbine in women with previously treated advanced breast cancer: a US multi-center phase II trial. Proc Annu Meet Am Soc Clin Oncol 13: A105
67. Spielmann M, Dorval T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rouesse J, Pouillart P, Tursz T and Merle S (1994) Phase II Trial of Vinorelbine/Doxorubicin as first-line therapy of advanced breast cancer. Journal of Clinical Oncology 12: 1764-1770
68. The Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. JNCI 91: 66-72
69. Terenziani M, Demicheli R, Brambilla C, Ferrari L, Moliterni A, Zambetti M, Caraceni A, Martini C and Bonadonna G (1996) Vinorelbine: an active, non cross resistant drug in advanced breast cancer: results from a phase II study. Breast Cancer Res Treat 39: 285-291
70. Tononi A, Panzini I, Oliverio G, Pasquini E, Gianni L, Nicolini M and Ravaioli A (1997) Vinorelbine chemotherapy in non small cell lung cancer: experience in the elderly. J Chemother 9: 304-308
71. Twelves C, Dobbs N and Curnow A (1994) A phase II, mulitcentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 70: 990-993
72. Van Belle S, De Smet M, Monsaert C, Geerts F, Storme GE and Massart DI (1992) High performance liquid chromatographic determination of Navelbine in MO4 mouse fibrosarcoma cells and biological fluids. J Chromatogr 576: 351-357
73. Van Cantfort J and Cano JP (1989) Systemic bioavailability and pharmacokinetics of orally administered navelbine, pilot study. Invest New Drugs 7: 460
74. Veronesi A, Crivellari D, Magri MD, Cartei G, Mansutti M, Foladore S and Monfardini S (1996) Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 32A: 1809-1811
75. Vogel C, O'Rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, White R and McGuirt C (1999) Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Annal of Oncology 10: 397-402.
76. Vokes EE (1994) Oral Navelbine for advanced Stage IV NSCLC. Presented at the 7th World Conference on Lung Cancer, Colorado Springs
77. Vorobiof D, Goedhals L, Barnardt P, Gudgeon A, Van-Der-Merwe A, Smith L, Murray E, Pretorius D, Bassompierre P, Bergonzoli E, Delgado FM, Le-Pape I, Vurilion JP and Le-Couturier S (1997) Phase II study of IV Navelbine (NVB) and Doxorubicin (DOX) in previously untreated breast cancer (ABC). Proc-Annu-Meet-Am-Soc-Clin-Oncol 16: A693
78. Wang LG, Liu XM, Kreis W and Budman DR (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44: 355-361
79. Wang LG, Xiu XM and Chao DL (1999) Activation of MAP kinase during apoptosis mediated by vinorelbine in MCF-7 cells. Proc Am Assoc Cancer Res 40: 13
80. Weber BL, Vogel CL, Jones S, Harvey H, Hutchins L, Bigley J and Hohneker J (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13: 2722-2730
81. Weisenberg RC (1972) Microtubule formation in vitro in solutions containing low calcium concentrations. Science 117: 1104-1105
82. Wozinak A, Crowley J, Balcerzak S, Weiss GR, Spiridonidids CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR and Livingston RB (1998) Randomised trial comparing Cisplatin with Cisplatin plus Vinorelbine in the treatment of advanced non-small cell lung cancer. A South West Oncology Group Study. JCO 16: 2459-2465